Literature DB >> 7736513

Linking radiosilver to monoclonal antibodies reduced by ascorbic acid. Comparison of results with stable silver using gravimetric technique and silver 110-M using radiotracer technique.

D K Hazra1, V L Lahiri, A K Gupta, N K Painuly, M Pathak, P Khanna, R K Gupta, P Khanna-Hazra, S Saran.   

Abstract

Radiosilver-111 and Radiogold-199 were proposed by us (1) as suitable isotopes for radioimmunotherapy in areas such as India by reason of their suitable half-lives and B-emissions (Ag-111 T1/2 = 7.45 d and Au-199 T1/2 = 3.15 d). Since silver is monovalent, it is difficult to link to conventional bifunctional chelates. We therefore explored the use of sulfur-based linkers (2). Encouraged by the Thakur and De Fulvio Technique (3) of linking technetium to disulfide groups in antibodies reduced by ascorbic acid that is eminently biocompatible, we have explored the linkage of silver to immunoglobulin reduced by ascorbic acid. The linkage of silver was assessed with stable Ag-108 using dialysis to quantify the free silver after the reaction of silver and reduced immunoglobulins in various molar ratios (1:1, 1:2, 1:5, 1:10). The silver quantity was estimated gravimetrically after precipitation as chloride. It was observed that using these molar ratios there was negligible silver efflux into the dialysate, suggesting stable linkage. We also assessed the linkage using Ag-110M as radiotracer. The comparative results with the two techniques are described.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7736513     DOI: 10.1007/bf02789209

Source DB:  PubMed          Journal:  Cell Biophys        ISSN: 0163-4992


  1 in total

1.  Determination of reduced disulfide groups in monoclonal antibodies.

Authors:  M L Thakur; J D DeFulvio
Journal:  Biotechniques       Date:  1990-05       Impact factor: 1.993

  1 in total
  1 in total

1.  Linkage of silver to antibodies through 2-imino thiolane.

Authors:  D K Hazra; G T Stevenson; K S Kan
Journal:  Cell Biophys       Date:  1995-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.